33558-75-7

Basic information

• Product Name: ALLYL(CHLOROMETHYL)DIMETHYLSILANE
• Synonyms: 3-CHLOROMETHYLDIMETHYLSILYL-1-PROPENE;ALLYL(CHLOROMETHYL)DIMETHYLSILANE;Silane, (chloromethyl)dimethyl-2-propen-1-yl-;chloromethyl-dimethyl-prop-2-enylsilane
• CAS NO: 33558-75-7
• Molecular Formula: C₆H₁₃ClSi
• Molecular Weight: 148.71
• Product Categories: Si (Classes of Silicon Compounds);Si-(C)4 Compounds;Silicon Compounds (for Synthesis);Synthetic Organic Chemistry;Vinylsilanes, Allylsilanes
• Mol File: 33558-75-7.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 63-66 °C50 mm Hg(lit.)
• Flash Point: 82 °F
• Appearance: /
• Density: 0.907 g/mL at 25 °C(lit.)
• Vapor Pressure: 7.3mmHg at 25°C
• Refractive Index: n20/D 1.449(lit.)
• CAS DataBase Reference: ALLYL(CHLOROMETHYL)DIMETHYLSILANE(CAS DataBase Reference)
• NIST Chemistry Reference: ALLYL(CHLOROMETHYL)DIMETHYLSILANE(33558-75-7)
• EPA Substance Registry System: ALLYL(CHLOROMETHYL)DIMETHYLSILANE(33558-75-7)

Safety Data

• Hazard Codes: Xi
• Statements: 10
• Safety Statements: 16
• RIDADR: UN 1993 3/PG 3
• WGK Germany: 3
• HazardClass: 3
• PackingGroup: III
• Hazardous Substances Data: 33558-75-7(Hazardous Substances Data)

Usage

Uses

Allyl(chloromethyl)dimethylsilane is a useful intermediate for the preparation of α-silyl alcohols, ethers, and amines.

InChI:InChI=1/C6H13ClSi/c1-4-5-8(2,3)6-7/h4H,1,5-6H2,2-3H3

Upstream product

• 1719-57-9 Chloro(chloromethyl)dimethylsilane 
• 106-95-6 allyl bromide 
• 1730-25-2 allylmagnesium bromide 
• 107-05-1 3-chloroprop-1-ene 
• 2622-05-1 allylmagnesium bromide 

Downstream Products

• 18442-84-7 (Allyl-dimethyl-silylmethyl)-phenyl-phosphinsaeure-ethylester 
• 1745-18-2 1-allyl-4-chlorobenzene 
• 439296-86-3 allyl(2-phenylaminoethyl)dimethylsilane 
• 54322-72-4 (1-chlorobut-3-en-1-yl)benzene 
• 13064-21-6 hepta-1,6-dien-4-ylbenzene 
• 97695-82-4 1-phenyl-3,3,5-trimethyl-1-aza-3-silacyclopentane 
• 36213-35-1 methyl 3-(dibutylphosphinyl)propionate 
• 88962-96-3 4-(di-n-butylphosphinyl)-4-phenylbutan-2-one 
• 122-57-6 1-Phenylbut-1-en-3-one 
• 18163-14-9 3,3-dimethyl-1-thia-3-silacyclopentane 
• 1833-51-8 chloromethyldimethylphenylsilane 
• 109790-06-9 (but-3-en-1-yl)dimethyl(phenyl)silane 
• 118722-59-1 2,2-dimethyl-1-<1-<(S)-2-(methoxymethyl)pyrrolidinyl>>-2-sila-4-pentene 

Relevant articles and documents

Cyclizations of 2-(Allyldimethylsilyl)ethyl Radicals

-

Conformational analysis of 3,3-dimethyl-3-silathiane, 2,3,3-trimethyl-3- silathiane and 2-trimethylsilyl-3,3-dimethyl-3-silathiane-preferred conformers, barriers to ring inversion and substituent effects

The first conformational analysis of 3-silathiane and its C-substituted derivatives, namely, 3,3-dimethyl-3-silathiane 1, 2,3,3-trimethyl-3-silathiane 2, and 2-trimethylsilyl-3,3-dimethyl-3-silathiane 3 was performed by using dynamic NMR spectroscopy and B3LYP/6-311G(d,p) quantum chemical calculations. From coalescence temperatures, ring inversion barriers δG≠ for 1 and 2 were estimated to be 6.3 and 6.8 kcal/mol, respectively. These values are considerably lower than that of thiacyclohexane (9.4 kcal/mol) but slightly higher than the one of 1,1-dimethylsilacyclohexane (5.5 kcal/mol). The conformational free energy for the methyl group in 2 (-°G0 - 0.35 kcal/mol) derived from low-temperature13C NMR data is fairly consistent with the calculated value. For compound 2, theoretical calculations give δE value close to zero for the equilibrium between the 2-Me ax and 2-Meeq conformers. The calculated equatorial preference of the trimethylsilyl group in 3 is much more pronounced (-δG0 - 1.8 kcal/mol) and the predominance of the 3-SiMe 3 eq conformer at room temperature was confirmed by the simulated1H NMR and 2D NOESY spectra. The effect of the 2-substituent on the structural parameters of 2 and 3 is discussed. Copyright

N-derivatives of 1-deoxy nojirimycin

This invention relates to novel N-derivatives of 1-deoxy nojirimycin, to the method for their preparation and to their use in the treatment of diabetes and the use against retro-viruses, particularly in the treatment of acquired immuno-deficiency syndrome